ProfileGDS5678 / 1435864_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 81% 77% 81% 81% 75% 70% 79% 79% 76% 79% 80% 65% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1649577
GSM967853U87-EV human glioblastoma xenograft - Control 25.879281
GSM967854U87-EV human glioblastoma xenograft - Control 35.2210477
GSM967855U87-EV human glioblastoma xenograft - Control 45.9807981
GSM967856U87-EV human glioblastoma xenograft - Control 55.7671581
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8888575
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.385470
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4636379
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.46379
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2045176
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5640379
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6765380
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9253865
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.624480